Advanced search
Start date
Betweenand

VASOHIBIN (VASH) as possible marker of carcinogenesis in colorectal adenocarcinoma

Grant number: 18/21906-1
Support type:Scholarships in Brazil - Scientific Initiation
Effective date (Start): June 01, 2019
Effective date (End): May 31, 2020
Field of knowledge:Health Sciences - Medicine
Principal Investigator:Denise Gonçalves Priolli
Grantee:Maycon Giovani Santana
Home Institution: Universidade São Francisco (USF). Campus Bragança Paulista. Bragança Paulista , SP, Brazil

Abstract

According to the World Health Organization, cancer is ranked as the second leading cause of death in the world, behind the diseases that affect the circulatory system. In Brazil, excluding non-melanoma skin cancer, colorectal cancer is the third most common in men and the second in women. Carcinogenesis is dependent on a sort of factors. It is described in three stages: initiation, promotion, and progression. The tumor progression requires the angiogenic process sufficient to its metabolic demand. The angiogenesis modulator, vasohibin is a functional protein that has an antiangiogenic activity, regulates the endothelial growth and proliferation mechanisms of tumor growth inhibition. However, this molecule is still not studied as colorectal carcinogenesis biomarker. For this study samples of healthy tissue, polyps adenomatous and adenocarcinoma colorectal will be submitted to the histology, microvessel counts, and immunohistochemical analysis using the antibody anti-VASH in order to analyze VASH and its action on vascular density in the different carcinogenesis stages. It is intended to determine the value of VASH as the diagnostic biomarker and/or prognosis in colorectal cancer.